Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03906292
Title Frontline Asciminib Combination in Chronic Phase CML (CMLXI)
Acronym CMLXI
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Jena
Age Groups: adult | senior
Covered Countries DEU

No variant requirements are available.